Groot, Carin A. Uyl-de; van Rooijen, Elisabeth M.; … - In: Health Economics Review 8 (2018) 13, pp. 1-8
Objective: To assess the cost effectiveness of cetuximab in third-line treatment of patients with KRAS wild-type (wt … was performed. Results: Administration of cetuximab in third-line treatment of mCRC resulted in a gain of 0.29 LYs and 0 …,527 per LY and QALY gained, respectively. Conclusions: Results of this cost-effectiveness analysis showed that third-line …
